The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement

China National Center for Cardiovascular Diseases124 enrolled

Overview

A study to evaluate the effectiveness and safety of levosimendan compared with placebo in subjects with severe aortic stenosis and heart failure undergoing transcatheter aortic valve replacement

The number of subjects undergoing transcatheter aortic valve replacement to treat aortic stenosis have been increasing in recent decades. Levosimendan, an innovative inotrope, is powerfully evidenced to have the function to improve cardiac output and hemodynamic parameters. However, there is no specified study concentrated on the role of Levosimendan in surgical procedure such as transcathter aortic intervention. This double-blind, randomized, placebo-controlled study is aimed to investigate the effectiveness and safety of Levosimendan in adults having severe aortic stenosis combined with heart failure undergoing transcatheter aortic valve replacement. Therefore, the purpose of this trial is to explore whether the improvement of cardiac and renal performance can be rendered by intra-operative Levosimendan infusion.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

124

Conditions

Aortic Valve Stenosis Heart Failure Inotropic Agents

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Signed (by the subjects or their legally acceptable representatives) informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study 2. Severe aortic stenosis 1. Mean transaortic gradient ≥ 40 mmHg(at rest or stress) 2. Aortic peak velocity ≥ 4m/s; 3. Arotic valve area \<0.8 cm2 and/or aortic valve area index\< 0.5cm2/m2 3. Cardiac dysfunction 1. LVEF≤50% (estimated by Simpson) 2. NT-proBNP≥1500ng/L； 3. Symptoms of dyspnea and fatigue when at rest or after slight exertion (New York Heart Association ≥ Ⅲ -Ⅳ) 4. Intermittant fluid retention and/or symptoms induced by low cardiac output at rest, but lack of hemodynamic instability Exclusion Criteria: 1. Decompensated acute cardiac failure due to hemodynamic instability 2. A historty of torsade de points ventricular tachycardia 3. Known allergic reaction or sensitivity to Levosimendan or excipients 4. Received levosimendan within 1 week prior to the planned clinical trial 5. Serum potassium \< 3.5 mmol/L and \> 5.5 mmol/L before the drug study 6. Systolic blood pressure \< 90mmHg at baseline 7. Estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m2. 8. Unable to participate in study for being critically ill asssed by clinicians 9. Other concomitant severe morbidities leading to poor prognosis and decreased mortality, such as malignant tumor and disease involving other vital organs; life expectancy less than 1 year.